Carsten S.
- Country
- Germany
- Department
- Mukoviszidosezentrum Potsdam
Research Overview
- Phase 2 Randomized Double‑Blind Study of VX-828/Deutivacaftor With and Without Tezacaftor in Adults with Cystic Fibrosis
- Evaluation of Long-term Safety and Efficacy of Tezacaftor, Deutivacaftor, and Vanzacaftor Combination Therapy in Patients with Cystic Fibrosis
- Long-term Safety and Efficacy Evaluation of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Non-F508del CFTR Genotypes
Data & Insights
Has run more than one trial at 71 of 214 partner sites.
Specializations
Respiratory Medicine
This investigator specializes in the treatment of cystic fibrosis, conducting extensive research into innovative therapeutic approaches for managing this genetic condition.
- Genetic respiratory disorders
- Advanced inhalation therapies
- Novel therapeutic combinations
Their work encompasses evaluation of various treatment modalities for improving respiratory function in cystic fibrosis patients.
Clinical Therapeutics
The investigator focuses on assessing long-term safety profiles and tolerability of innovative therapeutic compounds for chronic respiratory conditions.
- Drug safety assessment
- Therapeutic tolerability
- Dose optimization studies
Their expertise includes evaluating multiple therapeutic approaches through carefully designed clinical investigations.
Treatment Innovation
The investigator specializes in studying combination therapies and targeted treatments for genetic respiratory disorders.
- Advanced therapeutic compounds
- Inhalation treatment methods
- Treatment efficacy evaluation
Their research encompasses both established and experimental therapeutic approaches in respiratory medicine.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.